This company listing is no longer active
4CX Stock Overview
A clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Cyxone AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0002 |
| 52 Week High | SEK 0.03 |
| 52 Week Low | SEK 0.0001 |
| Beta | 0.44 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -95.24% |
| 3 Year Change | -99.88% |
| 5 Year Change | -99.95% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4CX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 6.5% | 1.3% |
| 1Y | -95.2% | -1.9% | 9.0% |
Return vs Industry: 4CX underperformed the German Biotechs industry which returned -10.5% over the past year.
Return vs Market: 4CX underperformed the German Market which returned 9.2% over the past year.
Price Volatility
| 4CX volatility | |
|---|---|
| 4CX Average Weekly Movement | 1,208.9% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4CX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4CX's weekly volatility has decreased from 5522% to 1209% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Kjell Stenberg | www.cyxone.com |
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
Cyxone AB (publ) Fundamentals Summary
| 4CX fundamental statistics | |
|---|---|
| Market cap | €586.93k |
| Earnings (TTM) | -€1.93m |
| Revenue (TTM) | €305.85k |
1.9x
P/S Ratio-0.3x
P/E RatioIs 4CX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4CX income statement (TTM) | |
|---|---|
| Revenue | SEK 3.52m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 3.52m |
| Other Expenses | SEK 25.68m |
| Earnings | -SEK 22.16m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 100.00% |
| Net Profit Margin | -629.96% |
| Debt/Equity Ratio | 0% |
How did 4CX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 14:07 |
| End of Day Share Price | 2024/12/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyxone AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maria Karlsson Osipova | Penser Access |